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Abstract
Background:  Concomitant chemotherapy and radiotherapy (chemoradiation; CRT) is the
standard treatment for locoregionally advanced squamous cell carcinoma of the head and neck (LA-
SCCHN). CRT improves local control and overall survival (OS) when compared to radiotherapy
(RT) alone. Induction chemotherapy (IC) reduces the risk of distant metastases (DM) and improves
OS by 5% with the use of cisplatin/infusional 5 fluorouracil (PF) in meta-analysis. Adding a taxane
to PF in the IC regimen confers a better outcome. Sequential treatment (ST) of IC followed by CRT
is therefore under active investigation in multiple phase III trials.
Methods: We compared the outcome of two cohorts of patients (pts) with LA-SCCHN treated
at our institution with CRT (n = 27) or ST (n = 31), respectively. CRT consisted of GEM 100 mg/
m2 weekly + conventional RT (70 Gy); ST consisted of the same CRT preceded by platinum-based
IC.
Results: Response to IC: complete 8 (26%), partial 20 (65%), stable 1, progressive 1, not evaluable
1. Median follow up of the surviving pts: for CRT 73 months, for ST 51 months. Median time to
distant metastasis (TDM) was for CRT 23.6 months, for ST not reached. Median OS was for CRT
20.2 months, for ST 40.2 months. Cox regression analysis, taking into account age, T and N stage
and tumor site, showed a hazard ratio with ST of 1.190 for time to locoregional failure (p = 0.712),
0.162 for TDM (p = 0.002), and 0.441 for overall survival (OS) (p = 0.026).
Conclusion: TDM and OS were found significantly longer in the ST cohort without a reduced
locoregional control. Notwithstanding the limitations of a non-randomized single-center
comparison, the results are in line with very preliminary data of randomized comparisons
suggesting an improved outcome with ST.
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Background
Two thirds of the squamous cell carcinoma of the head
and neck (SCCHN) are in a locoregionally advanced dis-
ease stage at time of diagnosis. Locoregionally advanced
SCCHN is generally treated by a combination of chemo-
therapy and irradiation with or without surgery [1]. Con-
current chemotherapy and radiotherapy
(chemoradiation) is widely adopted as standard of care
for locoregionally advanced SCCHN after the publication
of a large meta-analysis including individual data on
10.741 patients in 63 randomized trials [2,3]. Concurrent
chemoradiation conferred an absolute survival benefit of
8% at 2 and 5 years. In contrast, the meta-analysis failed
to demonstrate a survival advantage for induction chemo-
therapy followed by local treatment compared to local
treatment alone. However when the meta-analysis was
restricted to trials using the standard cisplatin/infusional
5-fluorouracil (PF) regimen, the absolute benefit at 5
years was 5% (p = 0.05). Recently, the addition of a tax-
ane, docetaxel or paclitaxel, to cisplatin and 5-fluorouracil
induction chemotherapy has shown to further improve
response rates and survival outcomes when compared to
the standard PF combination [4-6].
Moreover, induction chemotherapy reduces the risk of
distant metastasis and offers the opportunity of assessing
tumor chemosensitivity and selecting the patients who are
candidate for organ preservation [7]. Sequential adminis-
tration of induction chemotherapy followed by concur-
rent chemoradiation might combine the benefits of both
[8]. Several cooperative groups are currently comparing
this sequential approach to standard chemoradiation.
However, definitive results of these randomized trials will
not be available for several years. We therefore decided to
perform a historical comparison of two cohorts of
patients who were treated at our institution either by gem-
citabine-based chemoradiation or induction chemother-
apy followed by the same chemoradiation regimen.
Methods
Patients
Eligible patients were those with histologically confirmed
locoregionally advanced SCCHN which were considered
not to be amenable to surgery by a multidisciplinary ded-
icated team of head and neck surgeons, radiation oncolo-
gists and medical oncologists. Other criteria included age
≥ 18, World Health Organization performance status ≤ 2,
adequate organ function, no prior chemotherapy and no
radiotherapy above the clavicles, no evidence of other syn-
chronous neoplasms, no evidence of distant metastases.
Patients participated in in-house protocols from 1998 to
2006, of chemoradiation and/or induction chemotherapy
regimens for which institutional review board approved
informed consent was required.
Treatment
All patients received weekly gemcitabine concurrently
with radiation. Planned cumulative radiation dose was 70
Gy which was administered in 35 conventional fractions
of 2 Gy over 7 weeks. Gemcitabine was started on the
same day as the radiotherapy and was administered intra-
venously (dissolved in 150 ml NaCl 0.9%) over 30 min-
utes at a dose of 100 mg/m2  within 2 hours before
radiotherapy. Four patients in the sequential cohort
received a lower gemcitabine dose (50 mg/m2 in one
patient and 10 mg/m2 in three patients) while participat-
ing in an in-house protocol exploring serum levels of gem-
citabine's metabolite difluorodeoxyuridine. In all cases
gemcitabine was given for the duration of radiotherapy. In
the sequentially treated cohort this same chemoradiation
regimen was preceded by at least one cycle of cisplatin-
based combination chemotherapy.
Study design
This is a non-randomized comparison of two cohorts of
patients treated at the Antwerp University Hospital by
either a gemcitabine-based chemoradiation program or
the same chemoradiation regimen preceded by cisplatin-
based combination chemotherapy, the sequential treat-
ment program. The objectives of this analysis were to
compare the time to locoregional relapse, time to distant
metastases, progression-free survival, overall survival and
toxicities between these two cohorts. Time to locoregional
failure (TLF) was defined as the time in months from the
first day of treatment to the date locoregional relapse was
recorded; time to distant metastases (TDM) was defined
as the time in months from the first day of treatment to
the date distant metastases were diagnosed; progression-
free survival (PFS) was defined as the time in months from
the first day of treatment to any form of progression event
or death; overall survival time (OS) was defined as the
time in months from the first day of treatment to the day
of death.
Assessments
Baseline tumor assessment was required within four
weeks before registration as measured by computed tom-
ography (CT) or magnetic resonance imaging (MRI) and
direct endoscopy. Tumor response was assessed by repeat-
ing CT or MRI and endoscopy after two and four cycles of
induction chemotherapy (or before chemoradiation in
case less than four cycles were administered) and three
months after the end of chemoradiation. World Health
Organization criteria were used to determine response
and disease progression. Endoscopy was performed at
each visit at the multidisciplinary outpatient clinic. Imag-
ing was repeated at any time disease progression was sus-
pected.BMC Cancer 2009, 9:273 http://www.biomedcentral.com/1471-2407/9/273
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Statistical analysis
Crude comparison of time to event variables (TLF, TDM,
PFS and OS) was based on Kaplan Meier analysis with log-
rank testing. A multiple Cox regression analysis, taking
into account age, T and N stage and tumor site, was used
to calculate adjusted hazard ratios. All statistical tests
comparing the two cohorts were two-sided using a signif-
icance level of α = 5%. The SPSS 13 software was used for
all calculations.
Results
Twenty-seven patients were treated in the concurrent
chemoradiation cohort and 31 patients in the sequential
cohort.
Patient and tumor characteristics are summarized in table
1 and 2. Median age was similar in both cohorts. There
were slightly more male patients in the sequential cohort.
Hypopharynx tumors predominated in the concurrent
cohort wile oropharynx tumors constituted the largest
group in the sequential cohort. Almost all tumors were
stage IV in both cohorts while all patients had a good or
excellent performance status.
Concurrent chemoradiation cohort (CRT)
The patients in the CRT cohort received a median of 7
weekly cycles (range 28) of gemcitabine 100 mg/m2 and a
median cumulative radiation dose of 70 Gy. Radiation
dose was 70 Gy in 22 of the 27 patients. Radiation was
stopped at a cumulative dose of 66 Gy in 2 patients and at
68 Gy in 1 patient, either for toxicity or for practical rea-
sons. Two patients received a higher dose (77.6 Gy and
84.75 Gy, respectively). Both patients had tumors which
progressed while on treatment and went on with two daily
fractions of 1.2 and 1.5 Gy, respectively. One patient
refused further gemcitabine after 2 cycles of gemcitabine
and continued with radiotherapy alone. Median treat-
ment duration in the CRT cohort was 50 days (range:
3756 days).
Sequential treatment cohort (ST)
Patients in the ST received a median of 4 cycles of induc-
tion chemotherapy. Twenty-eight of the 31 patients
received a taxane containing triplet which was TPF (cispl-
atin 75 mg/m2 on day 1, docetaxel 75 mg/m2 on day 1 and
5 fluorouracil 750 mg/m2/day as a continuous infusion
on day 1 to 5 of a 3-weeks cycle) in 12 patients. In 3 of
these patients TPF was associated with weekly cetuximab
as part of a pilot study. Sixteen patients received DIP
(docetaxel 6075 mg/m2 on day 1, cisplatin 5075 mg/m2
on day 1 or 5, and ifosfamide 1 g/m2/day as a continuous
infusion on day 1 to 5 every 3 weeks). Two patients
received the standard PF regimen and one patient was
treated with carboplatin at an AUC of 5 and paclitaxel 175
mg/m2. Twenty-eight patients (90%) responded to induc-
tion chemotherapy. A clinical complete response was doc-
umented in eight patients (26%), a partial response in 20
(65%). The disease remained stable in one patient and
progressed on induction chemotherapy in one. Response
was not evaluable in one patient.
One patient in the ST cohort died after 2 administrations
of gemcitabine and 18 Gy, due to grade 4 mucositis, grade
4 neutropenia and septic shock, which were treatment-
Table 1: Patient and tumor characteristics
CRT ST
Characteristics* n = 27 n = 31 p
Age:
median (range), years 57 (4478) 58 (4171) 0.208*
Gender 1
male 22 26
female 5 5
WHO performance status 0.7734
07 1 0
12 0 2 1
Primary tumor site: 0.179**
oropharynx 7 14
hypopharynx 17 9
larynx 1 4
paranasal sinus 1 1
nasopharynx 1
unknown 1 2
Stage: **1
III 2 1 0.5931
IV 25 30
CRT = concurrent chemotherapy and radiotherapy
ST = induction chemotherapy followed by CRT
*: Fischer's exact; **: Pearson chi-square; 1: T: p = 0.807; N: p = 0.163
Table 2: Primary tumor extent and nodal status
Concurrent treatment cohort
N0 N1 N2 N3 All
Tx 11
T1 112
T2 112
T3 44
T4 6282 1 8
All 62 1 4 5 2 7
Sequential treatment cohort
N0 N1 N2 N3 All
Tx 22
1 112
2 11
3 617
4 41 3 2 1 9
All 42 1 6 3 1BMC Cancer 2009, 9:273 http://www.biomedcentral.com/1471-2407/9/273
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related. In one patient, radiotherapy was stopped at 66 Gy
because of toxicity and deteriorating general condition.
One patient had progressive disease at the end of induc-
tion chemotherapy and received 80.5 Gy in 2 daily frac-
tions of 1.2 Gy. The remaining 28 patients in the
sequential cohort received the planned 70 Gy. Median
duration of radiation treatment in the ST cohort was 49
days (range 1053).
Toxicities and survival
Toxicities are summarized in table 3. Both the hemato-
logic and nonhematologic toxicities during chemoradia-
tion scored higher in the ST cohort compared to the CRT
cohort, apart from dermatitis which was unexpectedly
more severe in the CRT cohort. A feeding tube was
required during chemoradiation in 81% of the patients in
the CRT cohort and in 97% of the patients in the ST
cohort. Sixteen patients (59%) in the CRT cohort were
alive without locoregional relapse after one year. None of
these patients was feeding tube dependent at that point.
Twenty-one (68%) were alive without locoregional
relapse after 1 year in the ST cohort. Seven of them (33%)
were still feeding tube dependent at that point.
Time to distant metastasis and overall survival are shown
in figure 1 and 2, respectively. Median follow-up of the
surviving patients was 73 months in the CRT cohort and
51 months in the ST cohort. We therefore censored all
patients at 60 months of follow-up. The median TDM was
23.6 months with CRT and not reached with ST (log rank
p = 0.010). Median OS was 20.2 months with CRT and
40.2 months with ST (log rank p = 0.100). However, mul-
tiple Cox regression analysis, taking into account age, T
and N stage and tumor site, showed a hazard ratio with ST
of 1.190 for TLF (p = 0.712), 0.162 for TDM (p = 0.002),
and 0.441 for OS (p = 0.026).
Discussion
Admittedly, the results of our analysis are to be inter-
preted with extreme caution as this is a non-randomized
historical comparison of a relatively small number of
patients treated at a single institution. Moreover, although
the chemoradiation regimen was the same in both
cohorts, it was not the currently widely accepted standard
which is cisplatin-based. However, gemcitabine is a
potent radiosensitizer which ensures excellent local con-
trol rates when added to radiation as treatment for locally
advanced head and neck cancer, albeit at the cost of acute
and late toxicity in excess of what is usually seen with cis-
platin-based chemoradiation [9]. The median overall sur-
vival in our CRT cohort (20.2 months) was very similar to
that observed in the chemoradiation arm of the Inter-
group Study conducted in patients with unresectable
squamous cell carcinoma of the head and neck (19.1
months) [10], at least suggesting that the difference
between the two cohorts in our comparison was not due
to a worse than expected outcome in the CRT cohort. In
that Intergroup Study the standard cisplatin regimen (100
mg/m2 on day 1, 22 and 42) was used. The locoregional
control rate in our patients was promising and not signif-
icantly affected by the administration of induction chem-
otherapy. Induction chemotherapy did not preclude
timely administration of radiotherapy, which is crucial as
a protracted duration of radiation has a negative impact
on treatment outcome [11-14]. The use of induction
chemotherapy was associated with a statistically signifi-
cant reduced risk of distant metastases. The reduction in
distant metastasis translated into a better overall survival
in a multiple Cox regression analysis taking into account
age, T and N stage and tumor site. A reduced risk of distant
metastasis has been a consistent observation in induction
chemotherapy trials [2,15-17]. Graf et al [18] published
the results of a non-randomised comparison of chemora-
diation and sequential therapy performed at the Charité
Medical School in Berlin. In contrast to our findings, local
control was significantly worse in the sequential cohort.
They observed a difference in overall survival in favor of
the concomitant cohort which approached statistical sig-
nificance. However, the radiation regimen in that study
differed between the two cohorts: patients in the chemo-
radiation cohort received a hyperfractionated course up to
72 Gy while the patients in the sequential cohort received
conventionally fractionated chemotherapy up to 70 Gy.
Moreover, mean radiation dose achieved in the sequential
cohort (65.3 Gy) was substantially lower than in the
Table 3: Toxicity
CRT ST
n = 27 n = 31
% (grade 3/4) % (grade 3/4)
During induction chemotherapy
Anemia NA 100 (19)
Neutropenia NA 94 (90)
Thrombocytopenia NA 74 (13)
Mucositis NA 13 (6)
Fatigue NA 61 (3)
Diarrhea NA 6 (3)
During chemoradiation
Anemia 100 (4) 97 (16)
Neutropenia 41 (4) 58 (13*)
Thrombocytopenia 30 (0) 61 (6)
Mucositis 100 (81) 100 (97)
Dermatitis 100 (74) 100 (42)
Weigth loss > 5% 63 69
> 10% 30 28
Tube feeding during CRT 81 97
at 1 year** 0 33***
*: 1 patient grade 5; **in patients alive without locoregional 
recurrence
***: 4/10 oropharynx and 3/5 hypopharynx; NA = not applicableBMC Cancer 2009, 9:273 http://www.biomedcentral.com/1471-2407/9/273
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chemoradiation cohort (71.6 Gy). Finally, patients in the
sequential cohort received only two cycles of PF induction
chemotherapy and only one additional course of chemo-
therapy during radiation.
In our study, patients received a median of 4 cycles of
chemotherapy which was a taxane containing triplet in
93%. Indeed, taxane containing triplets have demon-
strated clear superiority over PF when administered as
induction regimen. In our patients, induction chemother-
apy did not jeopardize the subsequent radiation therapy
as the median cumulative dose was 70 Gy in both cohorts.
All these factors taken together may explain the discordant
results of the analysis by Graf et al and ours.
Sequential treatment is associated with an increased toxic-
ity. Hematological toxicity dominates during the induc-
tion phase of the therapy. Some of the hematological
toxicity carries over to the chemoradiation phase. Of
greater concern is the difference of long term feeding tube
dependency rate between the two cohorts. Admittedly, the
numbers in our study are small and the outcome might be
different if cisplatin is used instead of gemcitabine. Never-
theless, we think this observation is noteworthy.
Thus far, the sequential administration of induction
chemotherapy followed by chemoradiation should still
be considered experimental and should not be used out-
side clinical trials. The short term feasibility of this para-
Time to distant metastasis Figure 1
Time to distant metastasis. Median: CRT: 23.6 months; ST: not reached; Cox regression analysis p = 0.002BMC Cancer 2009, 9:273 http://www.biomedcentral.com/1471-2407/9/273
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digm has been demonstrated both in phase II and in
phase III trials, but long term toxicity data are still lacking.
Moreover, the superiority of this approach over chemora-
diation alone in terms of efficacy has not been demon-
strated in a phase III direct comparison. At least four large
randomized phase III trials comparing TPF induction
chemotherapy followed by chemoradiation to chemora-
diation alone are currently planned or underway [7]. Data
of one of these phase III trials were presented by Hitt et al
[19]. TPF followed by irradiation and concurrent cisplatin
100 mg/m2 every 3 weeks was associated with a higher CR
rate and a better time to treatment failure than the same
concurrent chemoradiation regimen alone. Paccagnella
presented the final results of the phase II portion of an
Italian randomized trial which compares TPF followed by
irradiation in combination with cisplatin and 5-FU or the
same chemoradiation alone [20]. TPF induction chemo-
therapy did not compromise the delivery of the subse-
quent chemoradiation and did not increase the incidence
of severe radiation dermatitis or mucositis. The higher CR
rate in the sequential arm justified the initiation of the
phase III portion of the study.
Conclusion
In conclusion, our non-randomized comparison mirrors
the outcome of randomized trials which demonstrated a
reduced risk of distant metastasis with induction chemo-
therapy in LA-SCCHN. In a multiple Cox regression anal-
ysis, this reduced risk of distant metastasis translated in a
better overall survival. Locoregional control was not sig-
Overall survival Figure 2
Overall survival. Median: CRT: 20.2 months; ST: 40.2 months; Cox regression analysis p = 0.026BMC Cancer 2009, 9:273 http://www.biomedcentral.com/1471-2407/9/273
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nificantly affected by induction chemotherapy. Notwith-
standing the limitations of a non-randomized single-
centre comparison, the results are in line with the very pre-
liminary data of randomized comparisons, mentioned
above. Nevertheless, we suggest that the outcome of the
large randomized trials need to be awaited before the
sequential approach of induction chemotherapy followed
by chemoradiation can replace cisplatin-based chemora-
diation as the new standard treatment.
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